Literature DB >> 11054020

The versatility of cytokeratins as tumor markers.

T Stigbrand1.   

Abstract

Cytokeratins are particularly versatile tools in tumor biology both experimentally and clinically. Previously regarded as a rigid intracellular skeleton, the cytokeratins are now known to provide a more dynamic structural integrity within epithelial cells. This more flexible nature of cytokeratin function occurs through rapid shifts in assembly/disassembly states, geared by phosphorylations/dephosphorylations in the 'head' and 'tail' regions of the monomeric filaments. When released from proliferating or dying tumor cells, they provide a useful marker for epithelial malignancies, as evidenced by the number of available immunochemical assays for cytokeratins. Another significant area of interest that highlights their utility is the deposition of cytokeratins in the necrotic areas of tumors, providing an effective target for radioimmunotherapy and radioimmunolocalization. Moreover, the appearence of cytokeratin neodeterminants seems to be a very early event during apoptosis. Indeed, the involvement of specific cytokeratin degradation patterns resulting from the activity of caspases during apoptosis highlights yet another developing field of research devoted to these highly pleomorphic and complex structures. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11054020     DOI: 10.1159/000030148

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  8 in total

1.  Proteomic analysis of prodigiosin-induced apoptosis in a breast cancer mitoxantrone-resistant (MCF-7 MR) cell line.

Authors:  Marta Monge; Marta Vilaseca; Vanessa Soto-Cerrato; Beatriz Montaner; Ernest Giralt; Ricardo Pérez-Tomás
Journal:  Invest New Drugs       Date:  2007-02       Impact factor: 3.850

2.  E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.

Authors:  Narasimhan Kothandaraman; Vladimir B Bajic; Pang N K Brendan; Chan Y Huak; Peh B Keow; Khalil Razvi; Manuel Salto-Tellez; Mahesh Choolani
Journal:  BMC Cancer       Date:  2010-02-24       Impact factor: 4.430

3.  Circulating cytokeratin 18 fragments and activation of dormant tumor cells in bone marrow of cancer patients.

Authors:  Christoph Ausch; Veronika Buxhofer-Ausch; Ulrike Olszewski; Gerhard Hamilton
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

4.  Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma.

Authors:  Tarek G Gharib; Guoan Chen; Hong Wang; Chiang-Ching Huang; Michael S Prescott; Kerby Shedden; David E Misek; Dafydd G Thomas; Thomas J Giordano; Jeremy M G Taylor; Sharon Kardia; John Yee; Mark B Orringer; Samir Hanash; David G Beer
Journal:  Neoplasia       Date:  2002 Sep-Oct       Impact factor: 5.715

5.  Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours.

Authors:  Y Pan; R Xu; M Peach; C-P Huang; D Branstetter; W Novotny; R S Herbst; S G Eckhardt; P M Holland
Journal:  Br J Cancer       Date:  2011-10-27       Impact factor: 7.640

6.  Cytokeratin 14 and cytokeratin 18 expressions in reduced enamel epithelium and dentigerous cyst: Possible role in oncofetal transformation and histogenesis- of follicular type of adenomatoid odontogenic tumor.

Authors:  D K Shruthi; M C Shivakumar; Anand S Tegginamani; B Karthik; B I Chetan
Journal:  J Oral Maxillofac Pathol       Date:  2014 Sep-Dec

7.  Serum Caspase-Cleaved Cytokeratin (M30) Indicates Severity of Liver Dysfunction and Predicts Liver Outcome.

Authors:  Hani Oweira; Mahmoud Sadeghi; Daniel Volker; Markus Mieth; Ahmed Zidan; Elias Khajeh; Omid Ghamarnejad; Hamidreza Fonouni; Karl Heinz Weiss; Jan Schmidt; Imad Lahdou; Arianeb Mehrabi
Journal:  Ann Transplant       Date:  2018-06-08       Impact factor: 1.530

8.  Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer.

Authors:  Kaat De Clercq; Feifan Xie; Olivier De Wever; Benedicte Descamps; Anne Hoorens; An Vermeulen; Wim Ceelen; Chris Vervaet
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.